Search

Displaying results 2671 - 2680 of 9132 in total
  1. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. … AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  2. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. … As of February 2007 the development of AZD3409 had been discontinued.

  3. Drug

    Methimazole

    go.drugbank.com/drugs/DB00763
    ApprovedInvestigational

    options such as surgery or radioactive iodine therapy are inappropriate. … [A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive

  4. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    As of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure … As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment

  5. Drug

    Eluxadoline

    go.drugbank.com/drugs/DB09272
    ApprovedInvestigational

    Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). … Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces fluid/ion secretion resulting in improved symptoms

  6. Drug

    Delorazepam

    go.drugbank.com/drugs/DB01511
    IllicitInvestigational

    It may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam. … It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam.

    Products: DELORAZEPAM DOC GENERICI
  7. Drug

    Carbazochrome

    go.drugbank.com/drugs/DB09012
    ApprovedWithdrawn

    either at a local or systemic level [A19744]. … It is not FDA-approved but is available as tablets or IM/SC injections in the treatment of hemorrhages in a number of countries.

    International brands: Adcar AC
  8. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.

  9. Drug

    Pyrimethamine

    go.drugbank.com/drugs/DB00205
    ApprovedInvestigationalVet approved

    One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.

  10. Drug

    Flucytosine

    go.drugbank.com/drugs/DB01099
    ApprovedInvestigational

    A fluorinated cytosine analog that is used as an antifungal agent.